중증복합면역결핍증 진단 시장 - 세계 산업 규모, 점유율, 동향 : 질환 유형별, 검사 유형별(TREC, 전혈구 산정, 유전자 검사, 생화학 검사, 기타), 최종사용자별, 지역별, 경쟁별(2020-2030년)
Severe Combined Immunodeficiency Diagnosis Market - Global Industry Size, Share, Trends Segmented By Disease Type, By Test Type (TREC, Complete blood count, Genetic Test, Biochemical Test, others), By End User, By Region & Competition, 2020-2030F
상품코드:1692206
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
중증복합면역결핍증(SCID) 진단 세계 시장은 2024년 1억 8,260만 달러로 평가되며, 2030년까지 CAGR은 9.20%로 예측 기간 동안 괄목할 만한 성장을 이룰 것으로 예상됩니다.
중증복합면역결핍증(SCID)은 면역체계에 영향을 미치는 희귀하고 심각한 유전성 질환으로 감염에 매우 취약하며, SCID는 종종 버블보이병이라고 불리는데, 이는 이 질환을 앓고 있는 환자가 병원균에 노출되지 않기 위해 무균 환경에서 생활한 데서 비롯된 것입니다. SCID는 세포성 면역과 체액성 면역 모두에 심각한 결함을 초래합니다. 즉, 환자는 T세포의 기능(세포성 면역)이 심각하게 손상되고 항체를 생성하는 B세포의 기능(체액성 면역)이 결여된 경우가 많습니다. 중요한 면역세포의 부족 또는 기능 장애로 인해 SCID 환자는 박테리아, 바이러스, 곰팡이, 기생충을 포함한 다양한 감염에 매우 취약합니다. SCID의 증상은 주로 모체의 항체가 감소하는 생후 몇 개월에 나타나며, SCID에 걸린 영아는 치료에 반응하지 않는 지속적이고 심각한 감염을 경험할 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
1억 8,260만 달러
시장 규모 : 2030년
3억 719만 달러
CAGR : 2025-2030년
9.20%
급성장 부문
병원
최대 시장
북미
주요 시장 촉진요인
SCID 발병률 상승
주요 시장 과제
유전적 이질성
주요 시장 동향
환자의 지지와 인식
목차
제1장 제품 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 중증복합면역결핍증(SCID) 진단 세계 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
질환 유형별(X연쇄 SCID, ADA-SCID, 기타)
검사 유형별(TREC, 전혈구수(CBC), 유전자 검사, 생화학 검사, 기타)
최종사용자별(병원, 진단·연구기관, 기타)
지역별
기업별(2024년)
시장 맵
제6장 아시아태평양의 중증복합면역결핍증(SCID) 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제7장 유럽의 중증복합면역결핍증(SCID) 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제8장 북미의 중증복합면역결핍증(SCID) 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제9장 남미의 중증복합면역결핍증(SCID) 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 중증복합면역결핍증(SCID) 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
인수합병
제13장 세계의 중증복합면역결핍증(SCID) 진단 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
ARCHIMED SAS
PerkinElmer LAS Inc.
Health Research, Inc
Winfertility, Inc.
Portea Medical
LaCAR MDX Technologies
Labsystems Diagnostics Oy
Devyser Diagnostics AB
Leadiant Biosciences Inc.
Revcovi
제17장 전략적 제안
제18장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
Global Severe Combined Immunodeficiency (SCID) Diagnosis Market was valued at USD 182.60 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.20% through 2030. Severe Combined Immunodeficiency (SCID) is a rare and severe genetic disorder that affects the immune system, leaving individuals highly susceptible to infections. SCID is often referred to as the bubble boy disease, as individuals with this condition used to live in sterile environments to avoid exposure to pathogens. SCID results in a profound deficiency in both cellular and humoral immunity. This means that affected individuals have severely impaired T cell function (cellular immunity) and often lack functional B cells, which are responsible for producing antibodies (humoral immunity). Due to the absence or dysfunction of critical immune cells, individuals with SCID are extremely vulnerable to a wide range of infections, including bacterial, viral, fungal, and parasitic infections. These infections can be recurrent, severe, and life-threatening. Symptoms of SCID often appear in the first few months of life, as maternal antibodies wane. Infants with SCID may experience persistent, severe infections that do not respond well to treatment.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 182.60 Million
Market Size 2030
USD 307.19 Million
CAGR 2025-2030
9.20%
Fastest Growing Segment
Hospitals
Largest Market
North America
Key Market Drivers
Rising Incidence of SCID
Efforts to increase awareness and education among healthcare professionals and the public have led to more cases of SCID being identified and diagnosed. For instance, When federal health officials added severe combined immunodeficiency (SCID) to the Recommended Uniform Screening Panel (RUSP), a national guideline for newborn screening (NBS), in 2010, it remained unclear to what degree NBS would improve outcomes for babies diagnosed with SCID. Thirteen years later, a paper by the Primary Immune Deficiency Treatment Consortium (PIDTC) reveals that SCID identified through NBS increases overall survival for babies born with the condition. Babies with SCID lack a functioning immune system, making them vulnerable to fatal infections unless they are treated in infancy with a bone marrow transplant (BMT), also known as hematopoietic stem cell transplantation (HSCT), or clinical trial gene therapy. The new study from PIDTC is a retrospective analysis examining how various factors affected the survival of patients diagnosed with SCID across almost four decades. The paper focuses in particular on how the institution of population-based NBS impacted survival. In a study of 902 patients treated with BMT at 34 PIDTC centers, researchers examined data from several time periods beginning in 1982. They found that for the first three time periods, covering 28 years total, the five-year survival rate of SCID patients treated with BMT hovered at 72-73%. However, in the period from 2010-2018, corresponding to when states instituted NBS for SCID, five-year survival rose to 87%.
Key Market Challenges
Genetic Heterogeneity
SCID is not a single disorder but a group of rare genetic conditions, each caused by specific mutations in different genes. These mutations can affect various aspects of immune system development and function. As a result, there is a wide range of genetic mutations associated with SCID. Due to genetic heterogeneity, SCID is classified into multiple subtypes, each with distinct genetic causes. Common SCID subtypes include X-linked SCID, ADA-SCID, IL7R-SCID, and more. Accurate diagnosis requires identifying the specific genetic mutation responsible for the individual's condition. Diagnosing SCID involves a complex diagnostic process that includes clinical evaluation, immunological assays, and genetic testing. Genetic testing is often required to confirm the diagnosis and subtype, but selecting the appropriate genetic tests can be challenging due to the diversity of SCID-related genes. New, previously unidentified genetic mutations associated with SCID continue to be discovered through research. Identifying novel mutations adds complexity to diagnostic testing, as genetic tests must be updated to include these new variants. Some genetic tests for SCID may not cover the full spectrum of known SCID-related genes or mutations. This can result in a diagnostic gap, as certain mutations may be missed in standard testing panels. Genetic heterogeneity can lead to variability in the clinical presentation and severity of SCID. Two individuals with the same genetic subtype of SCID may exhibit different symptoms and clinical courses. This variability can complicate diagnosis and treatment planning. Genetic counseling is essential for families affected by SCID. The presence of various genetic mutations and subtypes can make genetic counseling complex, requiring a comprehensive understanding of the genetic basis of the condition.
Key Market Trends
Patient Advocacy and Awareness
Patient advocacy groups and organizations dedicated to SCID, such as the Immune Deficiency Foundation (IDF) and the SCID Angels for Life Foundation, play a crucial role in advocating for individuals and families affected by SCID. They provide support, resources, and a platform for raising awareness. Patient advocacy groups often work with policymakers to advocate for improved access to diagnostic testing, treatment, and research funding for SCID. They play a role in shaping healthcare policies related to rare diseases like SCID. Patient advocacy efforts can lead to increased research funding for SCID, driving advancements in diagnostic methods, treatments, and the understanding of the condition. Advocacy efforts have contributed to the inclusion of SCID in newborn screening programs in several regions. This has dramatically increased awareness about the importance of early diagnosis. Awareness campaigns target healthcare providers, including pediatricians and neonatologists, to ensure they recognize the signs and symptoms of SCID and refer infants for diagnostic testing. Public awareness campaigns, often initiated by patient advocacy groups, aim to educate the general population about SCID. These campaigns may include social media outreach, educational materials, and community events. Events like the International SCID Awareness Day, held on October 15th each year, help raise global awareness about the condition. It is an opportunity for patients, families, healthcare providers, and advocates to come together to educate the public. SCID cases that receive media coverage, such as documentaries or news stories, can significantly increase awareness and prompt individuals to seek diagnostic testing if they suspect SCID in their families.
Key Market Players
ARCHIMED SAS
PerkinElmer LAS Inc
Health Research, Inc
Winfertility Inc.
Portea Medical
LaCAR MDX Technologies
Labsystems Diagnostics Oy
Devyser Diagnostics
Revcovi
Leadiant Biosciences Inc.
Report Scope:
In this report, the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Severe Combined Immunodeficiency (SCID) Diagnosis Market, By Disease Type:
X-linked SCID
ADA-SCID
others
Severe Combined Immunodeficiency (SCID) Diagnosis Market, By Test Type:
TREC
Complete blood count (CBC)
Genetic Test
Biochemical Test
Others
Severe Combined Immunodeficiency (SCID) Diagnosis Market, By End-User:
Hospitals
Diagnostic and Research Laboratories
Others
Severe Combined Immunodeficiency (SCID) Diagnosis Market, By region:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.
Available Customizations:
Global Severe Combined Immunodeficiency (SCID) Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (X-linked SCID, ADA-SCID, others)
5.2.2. By Test Type (TREC, Complete blood count (CBC), Genetic Test, Biochemical Test, others)
5.2.3. By End User (Hospitals, Diagnostic and Research Laboratories, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. Asia Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Test Type
6.2.3. By End User
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Test Type
6.3.1.2.3. By End User
6.3.2. India Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Test Type
6.3.2.2.3. By End User
6.3.3. Australia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Test Type
6.3.3.2.3. By End User
6.3.4. Japan Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Disease Type
6.3.4.2.2. By Test Type
6.3.4.2.3. By End User
6.3.5. South Korea Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Disease Type
6.3.5.2.2. By Test Type
6.3.5.2.3. By End User
7. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Test Type
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Test Type
7.3.1.2.3. By End User
7.3.2. Germany Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Test Type
7.3.2.2.3. By End User
7.3.3. Spain Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Test Type
7.3.3.2.3. By End User
7.3.4. Italy Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Test Type
7.3.4.2.3. By End User
7.3.5. United Kingdom Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Test Type
7.3.5.2.3. By End User
8. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Test Type
8.2.3. By End User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Test Type
8.3.1.2.3. By End User
8.3.2. Mexico Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Test Type
8.3.2.2.3. By End User
8.3.3. Canada Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Test Type
8.3.3.2.3. By End User
9. South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Test Type
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Test Type
9.3.1.2.3. By End User
9.3.2. Argentina Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Test Type
9.3.2.2.3. By End User
9.3.3. Colombia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Test Type
9.3.3.2.3. By End User
10. Middle East and Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Test Type
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Test Type
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Test Type
10.3.2.2.3. By End User
10.3.3. UAE Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Test Type
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market: SWOT Analysis
